Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Onco Targets Ther
2015 Jan 05;8:117-23. doi: 10.2147/OTT.S74820.
Show Gene links
Show Anatomy links
Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
Doval D
,
Prabhash K
,
Patil S
,
Chaturvedi H
,
Goswami C
,
Vaid A
,
Desai S
,
Dutt S
,
Veldore V
,
Jambhekar N
,
Mehta A
,
Hazarika D
,
Azam S
,
Gawande S
,
Gupta S
.
???displayArticle.abstract???
BACKGROUND: Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a common feature observed in lung adenocarcinoma. A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in a subset of non-small-cell lung cancer (NSCLC) tumors. The objective of this study was to determine the prevalence of EGFR mutations and EML4-ALK fusions in Indian patients with NSCLC (adenocarcinoma) as well as evaluate their clinical characteristics.
PATIENTS AND METHODS: Patients with NSCLC, adenocarcinoma histology, whose tumors had been tested for EGFR mutational status, were considered for this study. ALK gene rearrangement was detected by fluorescence in situ hybridization using the Vysis ALK Break Apart Rearrangement Probe Kit. ALK mutation was tested in samples that were negative for EGFR mutation.
RESULTS: A total of 500 NSCLC adenocarcinoma patients were enrolled across six centers. There were 337 (67.4%) men and 163 (32.6%) women with a median age of 58 years. One hundred and sixty-four (32.8%) blocks were positive for EGFR mutations, whereas 336 (67.2%) were EGFR wild-type. Of the 336 EGFR-negative blocks, EML4-ALK fusion gene was present in 15 (4.5%) patients, whereas 321 (95.5%) tumors were EML4-ALK negative. The overall incidence of EML4-ALK fusion gene was 3% (15/500).
CONCLUSION: The incidence of EGFR mutations (33%) in this Indian population is close to the reported incidence in Asian patients. EML4-ALK gene fusions are present in lung adenocarcinomas from Indian patients, and the 3% incidence of EML4-ALK gene fusion in EGFR mutation-negative cases is similar to what has been observed in other Western and Asian populations. The mutual exclusivity of EML4-ALK and EGFR mutations suggests implementation of biomarker testing for tumors harboring ALK rearrangements in order to identify patients that can benefit from newer targeted therapies.
Bang,
The potential for crizotinib in non-small cell lung cancer: a perspective review.
2011, Pubmed,
Echinobase
Bang,
The potential for crizotinib in non-small cell lung cancer: a perspective review.
2011,
Pubmed
,
Echinobase
Chougule,
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
2013,
Pubmed
Cortes-Funes,
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
2005,
Pubmed
Desai,
A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.
2013,
Pubmed
,
Echinobase
Dogan,
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
2012,
Pubmed
Doval,
Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study.
2013,
Pubmed
Fukui,
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
2012,
Pubmed
,
Echinobase
Huang,
Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.
2011,
Pubmed
Jang,
EGFR and KRAS mutations in patients with adenocarcinoma of the lung.
2009,
Pubmed
Jemal,
Cancer statistics, 2008.
2008,
Pubmed
Krishnamurthy,
The relevance of "Nonsmoking-associated lung cancer" in India: a single-centre experience.
2012,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
2012,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Malik,
Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India.
2013,
Pubmed
Mehta,
Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population.
2013,
Pubmed
Okamoto,
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.
2010,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Paik,
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
2012,
Pubmed
Popat,
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
2011,
Pubmed
Reck,
Management of non-small-cell lung cancer: recent developments.
2013,
Pubmed
Rikova,
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
2007,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Sahoo,
Screening for EGFR mutations in lung cancer, a report from India.
2011,
Pubmed
Sekine,
Emerging ethnic differences in lung cancer therapy.
2008,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Smits,
EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
2012,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Tanaka,
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
2012,
Pubmed
,
Echinobase
Tanaka,
Frequency of and variables associated with the EGFR mutation and its subtypes.
2010,
Pubmed
Tsao,
The future of NSCLC: molecular profiles guiding treatment decisions.
2011,
Pubmed
Usui,
The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases.
2011,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
Wu,
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.
2008,
Pubmed
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed